RNA

Worldwide Cell Analysis Industry to 2026 - Featuring Agilent Technologies, Danaher and Illumina Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, August 27, 2021

The "Cell Analysis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Analysis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global cell analysis market reached a value of US$ 16.4 Billion in 2020.
  • Cell analysis refers to an umbrella term for a wide variety of technologies that are utilized to study genetic and phenotypical characteristics of a cell.
  • Cell analysis is typically done to understand population heterogeneity, identifying minority sub-populations of interest, as well as discovering unique characteristics of individual cells.

Noxopharm Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19

Retrieved on: 
Thursday, August 26, 2021

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has reported preclinical data that further supports the role of experimental anti-cancer drug, idronoxil, the active ingredient in Veyonda , as an anti-inflammatory drug for early-stage COVID-19 treatments.

Key Points: 
  • Australian clinical-stage drug development company Noxopharm (ASX:NOX) has reported preclinical data that further supports the role of experimental anti-cancer drug, idronoxil, the active ingredient in Veyonda , as an anti-inflammatory drug for early-stage COVID-19 treatments.
  • These preclinical findings support preliminary top-line positive results the company shared earlier from its NOXCOVID Phase I clinical trial , which tested the suitability of idronoxil (Veyonda) as an effective anti-inflammatory in patients hospitalized with moderate COVID-19 disease.
  • Our latest findings, which are being prepared for publication, demonstrate that idronoxil may have applications in a range of diseases where TBK1 facilitates aberrant inflammation.
  • Veyonda has two main drug actions a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling.

Caris' Precision Oncology Alliance Welcomes The O'Neal Comprehensive Cancer Center at University of Alabama at Birmingham

Retrieved on: 
Thursday, August 26, 2021

The O'Neal Comprehensive Cancer Center at UAB is among the nation's leading cancer research institutions and one of only 51 comprehensive cancer centers designated by the National Cancer Institute (NCI).

Key Points: 
  • The O'Neal Comprehensive Cancer Center at UAB is among the nation's leading cancer research institutions and one of only 51 comprehensive cancer centers designated by the National Cancer Institute (NCI).
  • The O'Neal Comprehensive Cancer Center offers a full array of treatment options from multidisciplinary clinics filled with experts from across cancer fields to the latest state-of-the-art technology.
  • "The O'Neal Cancer Center is a national leader in driving cancer research, advancing new cancer treatments and leading cancer prevention and early detection initiatives," said Chadi Nabhan , M.D., MBA, FACP,Chairman of the Caris Precision Oncology Alliance.
  • The O'Neal Comprehensive Cancer Center at UAB is among the 51 cancer centers in the nation to meet the stringent criteria for the National Cancer Institute's comprehensive designation.

Agilex Biolabs Partners with Endpoints News for the First Webinar on Rapid Vaccine Development in Australia

Retrieved on: 
Thursday, August 26, 2021

Development of multiple COVID-19 vaccine candidates has been facilitated within Australia by the availability of high-quality contract research organizations such as Agilex Biolabs, and a favorable regulatory environment.

Key Points: 
  • Development of multiple COVID-19 vaccine candidates has been facilitated within Australia by the availability of high-quality contract research organizations such as Agilex Biolabs, and a favorable regulatory environment.
  • This webinar will cover the pathways that biotech companies can take for rapid vaccine development, and why Australia is the ideal location.
  • I am joined by my toxicology expert colleagues Dr Peter Tapley and Dr Drew Brockman for this detailed vaccine development webinar."
  • In this webinar Dr Sales and specialists from Agilex Biolabs' toxicology firm, TetraQ Toxicology will provide an overview of strategies to conduct vaccine development within Australia.

Avidity Biosciences Announces Changes to its Board of Directors

Retrieved on: 
Wednesday, August 25, 2021

Dr. Wong, managing partner and chief investment officer at RTW Investments, LP, joined Avidity's board in November 2019 in conjunction with the company's series C financing.

Key Points: 
  • Dr. Wong, managing partner and chief investment officer at RTW Investments, LP, joined Avidity's board in November 2019 in conjunction with the company's series C financing.
  • His experience in rare and genetic diseases is complementary to our existing board members and makes him a welcome addition to the Avidity team," said Sarah Boyce, president and CEO of Avidity.
  • "I am pleased to join the board of directors at Avidity, especially at such an exciting time for the company," said Mr. Mosbrooker.
  • Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCsTM).

Caribou Biosciences Appoints Nancy Whiting, Pharm.D., to its Board of Directors

Retrieved on: 
Wednesday, August 25, 2021

BERKELEY, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that it has appointed Nancy Whiting, Pharm.D., to its board of directors.

Key Points: 
  • BERKELEY, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that it has appointed Nancy Whiting, Pharm.D., to its board of directors.
  • I am delighted to welcome Nancy to our board of directors, said Rachel Haurwitz, Ph.D., Caribous president and chief executive officer.
  • Dr. Whiting most recently served as executive vice president, Corporate Strategy, Alliances and Communication for Seagen Inc. (formerly Seattle Genetics).
  • Caribou Biosciences and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

Aqueous Ozone by BES Group Proves Effective in Killing COVID-19

Retrieved on: 
Wednesday, August 25, 2021

SAN ANTONIO, Aug. 25, 2021 /PRNewswire/ -- Aqueous ozone by BES Group's Multi-Purpose Ozone Bottle and Professional Ozone Spray Bottle has proved effective in killing SARS-CoV-2, the virus that causes COVID-19 in testing by a third-party lab at Nara Medical University in Japan.

Key Points: 
  • SAN ANTONIO, Aug. 25, 2021 /PRNewswire/ -- Aqueous ozone by BES Group's Multi-Purpose Ozone Bottle and Professional Ozone Spray Bottle has proved effective in killing SARS-CoV-2, the virus that causes COVID-19 in testing by a third-party lab at Nara Medical University in Japan.
  • The Multi-Purpose Ozone Bottle was sprayed 5 times (1 time at 0.2 ml of aqueous ozone), and the Professional Ozone Spray Bottle was sprayed three times (1 time at 1.5 ml of aqueous ozone) on a petri dish with a sample of the COVID-19 virus.
  • Results show that using BES Group's ozone spray bottles are effective in preventing contact infection by the new coronavirus.
  • BES Group started from a lab looking for a solution to overcome traditional ozone generators that use air to generate ozone.

FDA Approves COMIRNATY®, The First COVID-19 Vaccine Approved By The Agency And The First COVID-19 Vaccine Brand Name Approved In The U.S.

Retrieved on: 
Wednesday, August 25, 2021

MIAMI, Aug. 25, 2021 /PRNewswire/ -- Brand Institute is proud to announce its role in naming Pfizer and BioNTech's FDA-approved COVID-19 vaccine: COMIRNATY® (koe mir' na tee). The name was first announced by Swiss regulatory authority, Swissmedic, in December of 2020, and by the European Medicines Agency (EMA) soon after. The brand name has also been approved by regulators in Japan and Australia, among other countries.

Key Points: 
  • The name was first announced by Swiss regulatory authority, Swissmedic, in December of 2020, and by the European Medicines Agency (EMA) soon after.
  • The brand name has also been approved by regulators in Japan and Australia, among other countries.
  • "The entire Brand Institute and Drug Safety Institute Team congratulates Pfizer and BioNTech on the FDA approval of COMIRNATY," said Brand Institute's Chairman and CEO, James L. Dettore.
  • FDA approval of a pharmaceutical or vaccine product's brand name is also a significant step toward the development of a global brand.

FDA Approves COMIRNATY®, The First COVID-19 Vaccine Approved By The Agency And The First COVID-19 Vaccine Brand Name Approved In The U.S.

Retrieved on: 
Wednesday, August 25, 2021

MIAMI, Aug. 25, 2021 /PRNewswire/ -- Brand Institute is proud to announce its role in naming Pfizer and BioNTech's FDA-approved COVID-19 vaccine: COMIRNATY® (koe mir' na tee). The name was first announced by Swiss regulatory authority, Swissmedic, in December of 2020, and by the European Medicines Agency (EMA) soon after. The brand name has also been approved by regulators in Japan and Australia, among other countries.

Key Points: 
  • The name was first announced by Swiss regulatory authority, Swissmedic, in December of 2020, and by the European Medicines Agency (EMA) soon after.
  • The brand name has also been approved by regulators in Japan and Australia, among other countries.
  • "The entire Brand Institute and Drug Safety Institute Team congratulates Pfizer and BioNTech on the FDA approval of COMIRNATY," said Brand Institute's Chairman and CEO, James L. Dettore.
  • FDA approval of a pharmaceutical or vaccine product's brand name is also a significant step toward the development of a global brand.

Noxopharm Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients

Retrieved on: 
Wednesday, August 25, 2021

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil ( Veyonda ), a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with moderate COVID-19 disease.

Key Points: 
  • Australian clinical-stage drug development company Noxopharm (ASX:NOX) has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil ( Veyonda ), a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with moderate COVID-19 disease.
  • Based on initial positive results, Noxopharm has started discussions to add Veyonda to one of the global clinical trial programs looking at identifying effective anti-inflammatory therapies in COVID-19 disease.
  • The NOXCOVID Phase I clinical trial is highly encouraging for Veyonda in this role as a high proportion of the patients were experiencing elevated inflammation, said Noxopharm CEO and Managing Director Graham Kelly .
  • In this trial, no major safety issues were identified and 37 of 38 patients hospitalized with moderate respiratory disease recovered.